Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Fri Mar 27, 6:40AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Amgen (AMGN) and Assembly Biosciences (ASMB) with bullish sentiments.

Claim 30% Off TipRanks Premium

Merck & Company (MRK)

Scotiabank analyst Louise Chen maintained a Buy rating on Merck & Company today and set a price target of $136.00. The company’s shares closed last Wednesday at $119.37.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.5% and a 47.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $131.41, a 12.0% upside from current levels. In a report issued on March 19, Goldman Sachs also maintained a Buy rating on the stock with a $133.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Amgen (AMGN)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen, with a price target of $432.00. The company’s shares closed last Wednesday at $353.93.

According to TipRanks.com, Amsellem is a 4-star analyst with an average return of 6.5% and a 50.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Collegium Pharmaceutical, and Fennec Pharmaceuticals. ;'>

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $366.70, implying a 4.5% upside from current levels. In a report issued on March 11, TD Cowen also maintained a Buy rating on the stock with a $420.00 price target.

Assembly Biosciences (ASMB)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences, with a price target of $50.00. The company’s shares closed last Wednesday at $28.67.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 23.9% and a 46.0% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

Currently, the analyst consensus on Assembly Biosciences is a Moderate Buy with an average price target of $45.00, a 58.2% upside from current levels. In a report issued on March 24, Mizuho Securities also maintained a Buy rating on the stock with a $40.00 price target.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).